There is provided a cell recovery method for recovering cells which are cultured in at least one container containing a liquid medium and adhere to an inner surface of the container, the method including performing: a medium discharge step of discharging the liquid medium from the container; a peeling liquid supply step of supplying a peeling liquid for peeling the cells from the inner surface of the container to the container; a peeling liquid discharge step of discharging the peeling liquid from the container before the cells are completely peeled from the inner surface of the container; a waiting step of waiting until the cells are peeled by action of a residual peeling liquid; and a recovery liquid supply step of supplying a recovery liquid for recovering the cells to the container.

Disclosed herein are methods for introducing functional mitochondria into liver cells in living animals (e.g., mammals). The disclosed compositions and methods can be used to treat clinical conditions characterized by genetic or acquired mitochondrial defects and the resulting dysfunctions and diseases therefrom.

The present invention provides a method of purifying highly pure retinal pigment epithelial cells from a cell population obtained by induction of differentiation of pluripotent stem cells into retinal pigment epithelial cells, by a simple and easy operation in a short period. The purification method of the present invention includes a step of introducing a cell population containing retinal pigment epithelial cells obtained by differentiation induction of pluripotent stem cells on laminin or a fragment thereof on a filter, and obtaining a cell population that passed the filter.

The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.

The present invention relates to a fetal cell capture module, a microfluidic chip for fetal cell capture, and methods for using the same. The fetal cell capture module comprises a cell capture carrier and recognition molecule(s) for specific capture the cell(s). The recognition molecule is attached to the surface of the carrier via an organic conjugate L comprising disulfide bonds. The surface of the chip is modified with recognition molecules that specifically capture fetal cells via organic conjugates comprising disulfide bonds. The recognition molecule, after capturing the cell, achieves the release of the cell by chemically cleaving the disulfide bonds in the organic coupling conjugate. The present invention enables the capture of fetal cell(s) from whole blood without pre-treatment with a high capture rate, low cell loss, simple and accurate cell release operation, and the efficient and noninvasive release of fetal cells and whole genome analysis.

A bioactive suspension derived from freshly disaggregated tissue is provided, as well as related methods of formulation and use. The bioactive suspension may comprise a cell-free supernate derived from epidermal and dermal tissue that has been enzymatically and mechanically disaggregated, then separated, and which may contain tissue regeneration factors known to speed healing. The bioactive suspension may further comprise genetically-modified treatment cells, wild type cells, or both, and may be combined with one or more scaffolding elements to form a bioactive suspension combination product suitable for treatment of a cutaneous defect. Synthetic bioactive suspensions and bioactive suspension combination products are also provided.

Tissue and cellular samples can be electrically dissociated into single cells and/or smaller groups of cells. The tissue samples can be housed in a device (which may also include a fluid) with one or more electrodes residing within the device. The device can be used to process one or more tissue samples. An electric field can be established through the device and the tissue samples can be dissociated into single cells and/or smaller groups of cells under the electric field.

An object of the present invention is to provide a production method for a synovium-derived mesenchymal stem cell, by which proliferation efficiency is improved so that a sufficient amount of synovium-derived mesenchymal stem cells can be obtained from a synovial tissue, a production method for a cell preparation for joint medical treatment using the production method for a synovium-derived mesenchymal stem cell, synovium-derived mesenchymal stem cell, and a cell preparation for a joint medical treatment. According to the present invention, there is provided a production method for a synovium-derived mesenchymal stem cell, which is a method of producing a synovium-derived mesenchymal stem cell from a synovial tissue, where the production method includes treating the synovial tissue with a mixed enzyme including one or more kinds of collagenases and one or more kinds of neutral proteases for 2 hours or more without causing the synovial tissue to undergo a disinfection step.

An object of the present invention is to provide a production method for a synovium-derived mesenchymal stem cell, which makes it possible to obtain a sufficient amount of synovium-derived mesenchymal stem cells from the synovial tissue, a production method for a cell preparation for joint medical treatment using the production method for a synovium-derived mesenchymal stem cell, synovium-derived mesenchymal stem cell, and a cell preparation for a joint medical treatment. According to the present invention, there is provided a production method for a synovium-derived mesenchymal stem cell, which includes treating a synovial tissue with an enzyme for 2 hours or more; and washing a mixture after the enzyme treatment until a residual enzyme concentration in a supernatant is 0.5 ng/mL or less, to obtain a synovium-derived mesenchymal stem cell.

A method is provided for producing a live cartilaginous material useful for implantation into a patient. A method of treating a patient comprising implanting a cartilaginous material prepared according to the provided method in an anatomical site in a patient also is provided.